Breakthrough in GI-Derived Bloodstream Infection Reduction: SER-155’s FDA Designation
Time: 10:30 am
day: Conference Day Two, Track One, AM
Details:
- Highlighting the significant reduction in bacterial bloodstream infections demonstrated in Phase 1b trials of SER-155 and its impact on patient outcomes
- Discussing the significance of FDA breakthrough therapy designation and fast track status for expedited development and regulatory collaboration
- Exploring the future development plans for SER-155, including its potential applications in various high-risk patient populations
